Table 1.
Baseline demographic and clinical characteristics of patients
| Characteristics | Total (n = 703) | |
|---|---|---|
| Age, years | 73 | [25‒94] |
| Male, n (%) | 564 | (80.2) |
| Body weight, kg, n (%) | ||
| < 60 | 323 | (45.9) |
| ≥ 60 | 380 | (54.1) |
| Time from the onset of primary HCC, years | 2.5 | [0.0‒20.6] |
| < 0.5 | 135 | (19.2) |
| ≥ 0.5, < 1 | 65 | (9.2) |
| ≥ 1, < 2 | 87 | (12.4) |
| ≥ 2, < 3 | 69 | (9.8) |
| ≥ 3, < 5 | 97 | (13.8) |
| ≥ 5, < 10 | 121 | (17.2) |
| ≥ 10 | 65 | (9.2) |
| Unknown | 64 | (9.1) |
| ECOG PS, n (%) | ||
| 0 | 533 | (75.8) |
| 1 | 148 | (21.1) |
| 2 | 11 | (1.6) |
| ≥ 3 | 5 | (0.7) |
| Unknown | 6 | (0.9) |
| BCLC stage, n (%) | ||
| 0/A | 59 | (8.4) |
| B | 291 | (41.4) |
| C | 332 | (47.2) |
| D | 11 | (1.6) |
| Unknown | 10 | (1.4) |
| Portal vein invasion, n (%) | ||
| No | 520 | (74.0) |
| Yes | 165 | (23.5) |
| Unknown | 18 | (2.6) |
| Extrahepatic lesions, n (%) | ||
| No | 450 | (64.0) |
| Yes | 229 | (32.6) |
| Unknown | 24 | (3.4) |
| Child-Pugh class, n (%) | ||
| A | 624 | (88.8) |
| B | 73 | (10.4) |
| C | 2 | (0.3) |
| Unknown | 4 | (0.6) |
| Etiology, n (%) | ||
| Hepatitis B virus | 137 | (19.5) |
| Hepatitis C virus | 287 | (40.8) |
| Alcohol | 167 | (23.8) |
| NAFLD/NASH | 88 | (12.5) |
| Others | 12 | (1.7) |
| Unknown | 59 | (8.4) |
| Treatment history, n (%) | ||
| Surgerya | 227 | (32.3) |
| Radiofrequency ablationb | 270 | (38.4) |
| Radiation therapyc | 93 | (13.2) |
| TKI therapy | 131 | (18.6) |
| TACE | 513 | (73.0) |
| HAIC | 74 | (10.5) |
| AFP level, ng/mL, n (%) | ||
| < 200 | 432 | (61.5) |
| ≥ 200 | 240 | (34.1) |
| Unknown | 31 | (4.4) |
Data are median [min‒max] or n (%). Percentages may not add up to 100.0 because of rounding
AFP alpha-fetoprotein, BCLC stage Barcelona Clinic Liver Cancer stage, ECOG PS Eastern Cooperative Oncology Group performance status, HAIC hepatic arterial infusion chemotherapy, HCC hepatocellular carcinoma, NAFLD/NASH non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, TACE transcatheter arterial chemoembolization, TKI tyrosine kinase inhibitor
aStatus was unknown for one patient
bStatus was unknown for one patient
cStatus were unknown for two patients